Metabolomics, metabolic flux analysis and cancer pharmacology

Liang, Lingfan; Sun, Fei; Wang, Hongbo; Hu, Zeping

doi:10.1016/j.pharmthera.2021.107827

Cited by 56 publications

(33 citation statements)

References 186 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Precision oncology aims at selecting the best therapy for the "right" patient by considering variables related to both specific features of each individual's unique disease, as well as the patient's health status [48] . One of the biological phenomena underlying precision oncology is the fact that, in cancer, cells reprogram their metabolism to support all phases of disease including tumor initiation, progression, and metastasis, as well as drug resistance [49] .…”

Section: Cancermentioning

confidence: 99%

“…Table 1 illustrates the concept of a personalized Table 1. A personalized approach based on metabolic analysis in some common types of cancer [48,[50][51][52][53]…”

Section: Cancermentioning

confidence: 99%

“…Breast Nuclear magnetic resonance metabolomics may be used for phenotyping of breast cancer patients, using different biospecimens, such as tissues, blood serum/plasma, and urine [48] Prostate Some urine metabolomics studies identified consistency in the dysregulation of 15 metabolites, while 18 metabolites were found consistently altered in the prostate tissue, including alanine, arginine, uracil, glutamate, fumarate, and citrate Of great interest are reports of altered valine, taurine, leucine, and citrate as the common denominators in both urine and tissue studies, thereby emphasizing the human metabolome as a promising target for identifying novel biomarkers for prostate cancer diagnosis [51] Ovaries Downregulation of both phospholipids and histidine, citrulline, alanine, and methionine were the most often observed biochemical changes. Compared to a single metabolite, the combination of multiple metabolites as a panel achieved a better diagnostic accuracy [52] Thyroid Identification of novel molecular markers of thyroid cancer promises to help identify distinct disease metabolic phenotypes, which may lead to a more personalized therapy while assisting in both the diagnosis and prediction of disease behavior [53] approach based on metabolic analysis in some common types of cancer.…”

Section: Colorectal (Crc)mentioning

confidence: 99%

“…Given that breast cancer is an extremely heterogeneous disease, it is necessary to carefully stratify patients to maximize their survival rates while optimizing their quality of life. For example, the risk of recurrence and the potential benefits from adjuvant chemotherapies may be estimated with gene-expression tools [48] . However, additional research is needed to further reduce the proportion of breast cancer patients who are potentially exposed to unnecessary chemotherapy, and additional prognostic and stratification tools are eagerly awaited.…”

Section: Breast Cancermentioning

confidence: 99%

See 3 more Smart Citations

Precision medicine approaches in metabolic disorders and target organ damage: where are we now, and where are we going?

Lonardo¹,

Byrne²,

Targher³

2021

MTOD

View full text Add to dashboard Cite

In this review, we discuss selected topics which are relevant to implementing precision medicine in metabolic disorders. Personalization of diet and exercise may help in preventing obesity and type 2 diabetes (T2D). Weight loss should be personalized based on age, sex, ethnicity, and coexisting comorbidities. Advances in our understanding of the pathophysiology, genetics, and epigenetics of obesity promise to offer tailored management options. Careful risk assessment is necessary prior to intervention. Risk may be underestimated, e.g., in women, in different ethnic groups, and in people with T2D. More personalized approaches could be useful among persons who failed to respond to traditional risk factor management, such as pharmacological treatment for dyslipidemia and arterial hypertension. Nonalcoholic fatty liver disease/metabolic-associated fatty liver disease (NAFLD/MAFLD) is both a cause and an effect of altered glucose and lipid metabolism. Personalized medicine approaches could be key to identify more effective pharmacological strategies as well as to reverse this common and burdensome metabolic liver disease. Finally, metabolomics could be used to identify relevant biomarkers for cancer diagnosis, staging, and prognostication. Cancers of the colon and rectum, breast, prostate, thyroid, and ovaries illustrate the notion that cancer cell metabolic derangements may be utilized in clinical practice. A true personalization of pharmacotherapies should be pursued especially in obese patients with cancer.

show abstract

Section: Cancermentioning

confidence: 99%

“…Table 1 illustrates the concept of a personalized Table 1. A personalized approach based on metabolic analysis in some common types of cancer [48,[50][51][52][53]…”

Section: Cancermentioning

confidence: 99%

Section: Colorectal (Crc)mentioning

confidence: 99%

Section: Breast Cancermentioning

confidence: 99%

See 2 more Smart Citations

Precision medicine approaches in metabolic disorders and target organ damage: where are we now, and where are we going?

Lonardo¹,

Byrne²,

Targher³

2021

MTOD

View full text Add to dashboard Cite

show abstract

“…Thus, to better understand lung cancer, the examination of downstream changes occurring at the level of the protein and metabolites might provide helpful information about the disease. Although there are a number of recent reviews on the topic of metabolomics in human health and disease [4][5][6][7][8][9][10][11][12][13], there is a paucity of information regarding the utility of metabolomics as a robust cancer diagnostic platform. Accordingly, the purpose of this brief review was to chart a general cancer diagnostic landscape and various approaches in the diagnosis of lung cancer, but with a major focus on the use of liquid biopsy.…”

Section: Introductionmentioning

confidence: 99%

Metabolomic Fingerprinting for the Detection of Early-Stage Lung Cancer: From the Genome to the Metabolome

Haince¹,

Joubert

Bach

et al. 2022

IJMS

View full text Add to dashboard Cite

The five-year survival rate of lung cancer patients is very low, mainly because most newly diagnosed patients present with locally advanced or metastatic disease. Therefore, early diagnosis is key to the successful treatment and management of lung cancer. Unfortunately, early detection methods of lung cancer are not ideal. In this brief review, we described early detection methods such as chest X-rays followed by bronchoscopy, sputum analysis followed by cytological analysis, and low-dose computed tomography (LDCT). In addition, we discussed the potential of metabolomic fingerprinting, compared to that of other biomarkers, including molecular targets, as a low-cost, high-throughput blood-based test that is both feasible and affordable for early-stage lung cancer screening of at-risk populations. Accordingly, we proposed a paradigm shift to metabolomics as an alternative to molecular and proteomic-based markers in lung cancer screening, which will enable blood-based routine testing and be accessible to those patients at the highest risk for lung cancer.

show abstract

Feasible mechanisms and therapeutic potential of food probiotics to mitigate diabetes‐associated cancers: A comprehensive review and in silico validation

Vinothkanna,

Shi‐Liang,

Karthick Rajan

et al. 2024

Food Frontiers

View full text Add to dashboard Cite

People with diabetes mellitus (DM) and hyperglycemia are linked with cancer risk. Diabetes and cancer have been corroborated by high morbidity and mortality rates. Studies revealed that elevated levels of insulin secretions trigger insulin‐like growth factor 1 (IGF‐1) production. Moreover, IGF‐1 is a key regulator involved in promoting cancer cell progression and is linked with DM. Cancer drug resistance and ototoxic effects can adversely affect the health and lifespan of an individual. However, naturally derived bioactive compounds are gaining attention for their nontoxic properties and specific behavior. Likewise, probiotics have also been regarded as safe and successful alternatives to treat DM‐linked cancers. The present review aims to highlight the therapeutic potential and feasible functions of probiotics to mitigate or inhibit DM‐associated cancers. Meanwhile, the intracellular signaling cascades involved in promoting DM‐linked cancer are enumerated for future prospective research. However, metabolomics interactions and protein–protein interactions are to be discussed for deeper insights into affirmative principles in diabetic‐linked cancers. Drug discovery and innovative preclinical evaluation need further adjuvant and immune‐enhancement therapies. Furthermore, the results of the in silico assessment could provide scientific excellence of IGF‐1 in diabetes and cancer. Overall, this review summarizes the mechanistic insights and therapeutic targets for diabetes‐associated cancer.

show abstract

Metabolomics, metabolic flux analysis and cancer pharmacology

Cited by 56 publications

References 186 publications

Precision medicine approaches in metabolic disorders and target organ damage: where are we now, and where are we going?

Precision medicine approaches in metabolic disorders and target organ damage: where are we now, and where are we going?

Metabolomic Fingerprinting for the Detection of Early-Stage Lung Cancer: From the Genome to the Metabolome

Feasible mechanisms and therapeutic potential of food probiotics to mitigate diabetes‐associated cancers: A comprehensive review and in silico validation

Contact Info

Product

Resources

About